Key facts
- Excellio Labs’s last known valuation is $1.8M (Jun 2025).
- It has raised $560K; the latest was Early Stage VC ($560K) in Jun 2025.
- Notable investors include Innovate UK, Old College Capital, Zinc, Cancer Tech Accelerator, LAUNCH.ed — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Excellio Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Excellio Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Excellio Labs
Developer of engineered exosome-based drug delivery systems designed for safe, tissue-specific therapeutic applications. The company's platform supports the development of delivery vehicles tailored for complex diseases such as cancer, neurodegeneration, cardiovascular disorders, and tissue regeneration, enabling clients with safe, efficient, and targeted drug delivery by transforming exosomes into programmable nanocarriers that overcome the limitations of conventional delivery systems.
- Sector
- Healthcare
- HQ
- Edinburgh, United Kingdom
- Founded
- 2023
- Employees
- 4
- Website
- excelliolabs.com/
- Ownership
- Privately Held (backing)
Excellio Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Excellio Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Excellio Labs in its N-PORT filings yet. We sweep new filings monthly.